Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Tenaya Therapeutics (TNYA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Company management will host investor meetings at both events.
A fireside chat from the H.C. Wainwright conference will be available on demand from September 11, 2026, via the Investors section of Tenaya’s website and will remain archived for about 30 days.
Tenaya Therapeutics (NASDAQ:TNYA) reported second quarter 2026 collaboration revenue of $1.1 million and a net loss of $43.4 million ($0.20 per share), compared with a $23.3 million loss a year earlier. The higher loss was mainly driven by a $21.8 million non-cash impairment and a $1.4 million lease-termination loss related to its decommissioned Genetic Medicines Manufacturing Center.
R&D expenses fell to $16.6 million and G&A to $5.4 million year over year. Cash and cash equivalents were $78.1 million at June 30, 2026, including a $10 million upfront payment from an Alnylam collaboration, which Tenaya expects will fund operations through Q3 2027. The Alnylam deal also includes potential milestones up to $1.1 billion.
Tenaya reported positive interim data from the MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) gene therapy trials, including improvements in cardiac hypertrophy, symptoms, and electrical stability, with no dose-limiting toxicities. Both TN-201 and TN-401 received EMA PRIME-related designations, and TN-201 entered the FDA’s Rare Disease Evidence Principles process. Additional interim data and pivotal-trial planning updates are anticipated in Q4 2026. TN-301 is advancing toward at least one Phase 2 proof-of-activity trial start in the second half of 2027.
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, Massachusetts, from August 11-12, 2026. Members of management will host 1x1 investor meetings, and CFO Eric Hyllengren will take part in a fireside chat on Tuesday, August 11, 2026, at 12:30 p.m. ET.
A live webcast and 30-day replay will be available in the Investors section of Tenaya’s website. Tenaya highlights a clinical pipeline including gene therapies TN-201, TN-401 and small molecule TN-301 targeting heart and related conditions.
Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to new employees under its 2024 Inducement Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The company granted options to purchase 1,650,000 shares of common stock to newly appointed CFO Eric Hyllengren and an aggregate of 187,200 shares to two new non-executive employees.
The options have a ten-year term and an exercise price of $0.8365 per share, equal to the closing price on July 13, 2026. Vesting occurs over four years, with 25% vesting on the one-year anniversary of hire and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.
Tenaya Therapeutics (NASDAQ:TNYA) appointed Eric Hyllengren as Chief Financial Officer effective July 13, 2026. He will lead financial strategy, capital allocation, investor relations and corporate development.
Hyllengren has over 20 years of biotech finance and strategy experience, including CFO roles at Zura Bio and Atara Biotherapeutics, where he executed more than $500 million in public financings. Tenaya also announced the planned Q3 2026 retirement of Hiro Higa, Senior Vice President, Finance, who will remain as a consultant to support a smooth transition.
Tenaya Therapeutics (NASDAQ:TNYA) reported interim MyPEAK-1 Phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated HCM.
Seven patients received TN-201; six were evaluable and showed reductions in left ventricular mass, improved NYHA class, KCCQ scores, exercise capacity, and favorable biomarker trends. TN-201 was generally well tolerated with no dose-limiting toxicities. The EMA granted PRIME designation and the FDA accepted a pediatric indication into the RDEP process. Enrollment at 6E13 vg/kg continues and Tenaya plans further long-term data in 2H 2026 and regulatory updates by year end.
Tenaya Therapeutics (NASDAQ:TNYA) will report new interim data from Cohorts 1 and 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Management will host a webcast at 8:00 a.m. ET, accessible via the Investors section under “Events & Presentations,” with an archived replay available for about 30 days.
Tenaya Therapeutics (NASDAQ:TNYA) will participate in the Jefferies Global Healthcare Conference 2026 in New York from June 2-4, 2026.
CEO Faraz Ali is scheduled to present on Thursday, June 4, 2026, at 3:10 p.m. ET, with live and archived webcasts available via Tenaya’s investor website.
Tenaya Therapeutics (NASDAQ:TNYA) reported positive interim data from Cohorts 1 and 2 of the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for PKP2-associated ARVC.
All six treated adults showed meaningful PVC burden reductions (mean 64%) with TN-401 well tolerated at 3E13 and 6E13 vg/kg and supported by biopsy evidence of cardiac transduction. TN-401 also received EMA PRIME designation.
Tenaya Therapeutics (NASDAQ: TNYA) reported Q1 2026 results and a business update on May 6, 2026. Cash and cash equivalents were $80.9M as of March 31, 2026, and Tenaya expects funding into the second half of 2027 including a $10.0M upfront from an Alnylam collaboration. The company highlighted upcoming clinical readouts for TN-201 and TN-401, preclinical TN-301 DMD data, FDA Rare Pediatric and Orphan designations for TN-301, and expanded research with Alnylam with milestones up to $1.1B.